PureTech Health, a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for complex diseases. Founded in 2015, PureTech has established itself as a leader in the healthcare industry, with a strong emphasis on advancing drug development in areas such as neuroscience, immunology, and gastrointestinal health. The company is renowned for its unique approach to drug discovery, leveraging its proprietary platform to identify and develop novel therapeutics. With a robust pipeline of products, including treatments for neurodegenerative disorders and immune-mediated diseases, PureTech Health is well-positioned in the market. Its commitment to addressing unmet medical needs has garnered recognition, making it a notable player in the biopharmaceutical landscape.
How does Puretech Health's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Puretech Health's score of 43 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, PureTech Health reported total carbon emissions of approximately 276,200 kg CO2e. This figure includes Scope 1 emissions of about 3,900 kg CO2e, Scope 2 emissions of approximately 57,000 kg CO2e (market-based), and Scope 3 emissions of around 107,700 kg CO2e. Comparatively, in 2022, the company’s total emissions were about 665,000 kg CO2e, with Scope 1 at 10,600 kg CO2e, Scope 2 at approximately 402,600 kg CO2e (market-based), and Scope 3 at about 251,900 kg CO2e. This indicates a significant reduction in total emissions year-on-year. PureTech Health has not disclosed any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. The company’s emissions data is not cascaded from a parent organisation, and all reported figures are derived directly from PureTech Health plc. Overall, while PureTech Health has made strides in reducing its carbon footprint, further commitments and targets would enhance its climate strategy.
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 33,300 | 00,000 | 00,000 | 000,000 | 00,000 | 0,000 |
| Scope 2 | 178,800 | 000,000 | 000,000 | 000,000 | 000,000 | 00,000 |
| Scope 3 | 1,199,900 | 000,000 | 000,000 | 000,000 | 000,000 | 000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Puretech Health has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

